Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
H Burris, A M Storniolo

Abstract

An early study with gemcitabine in pancreas cancer indicated greater relief of disease-related symptoms than expected from the objective tumour response rate. A novel design was created to assess changes in symptomatology prospectively in two studies. The design focuses on typical features seen in patients with advanced pancreas cancer (pain, impaired function, weight loss) and the endpoint is 'clinical benefit response'. Traditional endpoints of objective tumour response and survival were also included. In a randomised study, the clinical benefit response rate for gemcitabine was 24% compared with 5% for 5-fluorouracil (5-FU) (P = 0.0022). The median survival was 5.65 months for gemcitabine compared with 4.41 months for 5-FU (P = 0.0025). The corresponding objective response rates were 5.4% and 0%. Disease stabilised in 39% and 19% of gemcitabine and 5-FU patients, respectively. In a second study of 5-FU-refractory patients, 27.0% of patients were clinical benefit responders. The median survival in this second study was 3.8 months; the objective response rate was 11%, and 30% of patients had stable disease. These trials show that gemcitabine improves disease-related symptoms and survival in patients with pancreas cancer.

References

Jun 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E Van Cutsem, J Fevery
Jun 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R LionettoR Rosso
Jan 1, 1993·Journal of Pediatric Surgery·H C WardL Spitz
Apr 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M L RothenbergD D Von Hoff

❮ Previous
Next ❯

Citations

Feb 18, 2011·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Haruhiko ImamotoHitoshi Shiozaki
Jul 22, 2005·Investigational New Drugs·Basil F El-RayesPhilip A Philip
Sep 4, 2004·Current Treatment Options in Gastroenterology·Harold FruchtRobert L. Fine
Jun 18, 2002·Hematology/oncology Clinics of North America·Peter KozuchHoward W Bruckner
Jun 22, 2001·Critical Reviews in Oncology/hematology·D V GoldR M Sharkey
Sep 27, 2001·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·B MartinelliG Pinotti
Oct 19, 2012·Science Translational Medicine·Rohit ChughAshok K Saluja
Sep 6, 2011·Molecular Cancer Therapeutics·Dharmalingam SubramaniamShrikant Anant
Apr 26, 2012·Molecular Cancer Therapeutics·Dharmalingam SubramaniamShrikant Anant
May 9, 2012·The Journal of Clinical Investigation·Tewfik HamidiJuan Lucio Iovanna
Jan 20, 2007·Annals of Surgical Oncology·Yoshiyasu MitaYoshikazu Kuroda
Jul 30, 2014·World Journal of Gastroenterology : WJG·Atsushi SofuniTakao Itoi
Oct 5, 2013·Annals of Surgical Oncology·Jason A Castellanos, Nipun B Merchant
Sep 1, 2014·Current Treatment Options in Oncology·Terri S Armstrong, Mark R Gilbert
Feb 4, 2016·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Ya-Ping LiuYun-Xia Wu
Nov 17, 2009·Advanced Drug Delivery Reviews·Chitta Ranjan PatraPriyabrata Mukherjee
Mar 5, 2016·Cancer Chemotherapy and Pharmacology·Thierry WendlingLeon Aarons
Jul 15, 2015·International Journal of Pharmaceutics·Ravindra Dhar DubeyPrem N Gupta
Jun 1, 2008·Expert Review of Pharmacoeconomics & Outcomes Research·Michael BrundageJoseph Pater
Nov 4, 2000·Expert Opinion on Investigational Drugs·S R Bramhall
Feb 18, 2015·Materials Science & Engineering. C, Materials for Biological Applications·Zohreh BahramiBita Mehravi
Feb 4, 2014·Biochimica Et Biophysica Acta·Claudia FioriniMassimo Donadelli
Sep 20, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Domenico CilibertoPierosandro Tagliaferri
Mar 23, 2011·Nanomedicine : Nanotechnology, Biology, and Medicine·Soukaina RéjibaAmor Hajri
Oct 22, 2013·Cancer Letters·Serena LunardiThomas B Brunner
Jul 5, 2016·The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·Juehua YuF Charles Brunicardi
Jul 28, 2016·Current Opinion in Gastroenterology·Ashok K SalujaSulagna Banerjee

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
M NitscheH Schmidberger
Investigative Radiology
K Hynynen, B A Lulu
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Norisuke NakayamaKatsunori Saigenji
Swiss Surgery = Schweizer Chirurgie = Chirurgie Suisse = Chirurgia Svizzera
U HanackB Ringe
© 2021 Meta ULC. All rights reserved